SynthesisBreast cancer research and treatment2025
The significance of perioperative glucocorticoids in the prevention of seroma formation after mastectomies: a systematic review and meta-analysis.
Synthesis in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSeroma formation is one of the most common complications after mastectomy. Seromas can lead to repeated aspirations, increase the risk of infection, and potentially delay oncologic treatment. Several strategies have recently been employed to prevent seromas, but there is no definitive standard. We aim to determine whether perioperative glucocorticoids (GC) are safe and effective in preventing seromas in patients undergoing mastectomy.
methodsWe performed a systematic search in five databases on November 12, 2024. Eligible studies included women who underwent mastectomy and received perioperative GCs. Results are reported as risk ratios (RR), odds ratios (OR), or mean differences (MDs) with 95% confidence intervals (CIs), and are presented as forest plots. A random-effects model was used to pool effect sizes.
resultsAltogether, 13 studies (12 RCTs and 1 case-control study) with 1011 patients were included; all were eligible for meta-analysis. The rate of seroma formation was significantly lower in the GC groups compared to the placebo groups (RR = 0.56, CI 0.38; 0.82, p = 0,008). Total volume of drainage (MD = -213.36 ml, CI -312.5; -114.22, p = 0.001) and days to drain removal (MD =-3.01 days, CI -4.06; -1.96, p = 0.001) were also lower in the GC groups. The rate of wound infection showed a higher trend in the intervention groups (RR = 1.26, CI 0.82; 1.92, p = 0.224), although the results did not reach statistical significance,
conclusionsOur results suggest that perioperative glucocorticoid administration may reduce seroma formation in patients undergoing mastectomy. A potential increase in wound infection rates was also observed, but this requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.